Which patients with moderate hypoxemia benefit from long-term oxygen therapy? Ways forward

Forskningsoutput: TidskriftsbidragÖversiktsartikel

Abstract

Long-term oxygen therapy (LTOT) improves prognosis in patients with COPD and chronic severe hypoxemia. The efficacy in moderate hypoxemia (tension of arterial oxygen; on air, 7.4−8.0 kPa) was questioned by a recent large trial. We reviewed the evidence to date (five randomized trials; 1,191 participants, all with COPD). Based on the current evidence, the survival time may be improved in patients with moderate hypoxemia with secondary polycythemia or right-sided heart failure, but not in the absence of these signs. Clinically, LTOT is not indicated in moderate hypoxemia except in the few patients with polycythemia or signs of right-sided heart failure, which may reflect more chronic and severe hypoxemia.

Detaljer

Författare
Enheter & grupper
Externa organisationer
  • Hvidovre Hospital
Forskningsområden

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Lungmedicin och allergi

Nyckelord

Originalspråkengelska
Sidor (från-till)231-235
Antal sidor5
TidskriftInternational Journal of COPD
Volym13
StatusPublished - 2018 jan 9
PublikationskategoriForskning
Peer review utfördJa